Journal of gastrointestinal cancer · 2015
Shifting paradigm in the management of anal canal carcinoma.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mallick Supriya, Benson Rony, Julka P K, Rath G K
Аннотация
BACKGROUND: Anal canal is the lower most part of the gastrointestinal tract harbouring 4 % of all gastrointestinal cancer. Most common treatment for anal canal carcinoma includes chemoradiotherapy.
METHODOLOGY: We reviewed the recent landmark trials to find a road map in the management of anal canal carcinoma.
RESULTS: Concurrent chemoradiotherapy appears to be the most effective treatment schedule. Induction, as well as maintenance chemotherapy, has no definite role. Moderate dose radiation 50.4-54 Gy with concurrent mitomycin C (MMC) and 5-fluorouracil (5-FU) remains the standard. Split course is detrimental. Intensity-modulated radiotherapy and targeted drugs are investigated.
CONCLUSION: Combined modality therapy is the standard for anal canal carcinoma.
METHODOLOGY: We reviewed the recent landmark trials to find a road map in the management of anal canal carcinoma.
RESULTS: Concurrent chemoradiotherapy appears to be the most effective treatment schedule. Induction, as well as maintenance chemotherapy, has no definite role. Moderate dose radiation 50.4-54 Gy with concurrent mitomycin C (MMC) and 5-fluorouracil (5-FU) remains the standard. Split course is detrimental. Intensity-modulated radiotherapy and targeted drugs are investigated.
CONCLUSION: Combined modality therapy is the standard for anal canal carcinoma.